Intec Pharma Ltd (NTEC) Given Average Rating of “Buy” by Analysts
Intec Pharma Ltd (NASDAQ:NTEC) has received a consensus rating of “Buy” from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $13.30.
Several analysts have weighed in on NTEC shares. ValuEngine upgraded Intec Pharma from a “hold” rating to a “buy” rating in a research note on Saturday, December 1st. Oppenheimer set a $15.00 price target on Intec Pharma and gave the company a “buy” rating in a research note on Sunday, December 2nd. Zacks Investment Research upgraded Intec Pharma from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a research note on Thursday, December 6th. BidaskClub upgraded Intec Pharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 8th. Finally, HC Wainwright restated a “buy” rating and issued a $16.00 target price on shares of Intec Pharma in a research note on Monday, December 10th.
Institutional investors and hedge funds have recently modified their holdings of the company. PRW Wealth Management LLC purchased a new stake in shares of Intec Pharma in the fourth quarter worth about $29,000. Reilly Financial Advisors LLC purchased a new stake in shares of Intec Pharma in the fourth quarter worth about $38,000. BlackRock Inc. purchased a new stake in shares of Intec Pharma in the fourth quarter worth about $67,000. PNC Financial Services Group Inc. boosted its stake in shares of Intec Pharma by 50.0% in the third quarter. PNC Financial Services Group Inc. now owns 75,000 shares of the biotechnology company’s stock worth $424,000 after buying an additional 25,000 shares during the last quarter. Finally, Laurion Capital Management LP purchased a new stake in shares of Intec Pharma in the third quarter worth about $532,000. Hedge funds and other institutional investors own 36.43% of the company’s stock.
Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings results on Wednesday, February 27th. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.08). As a group, equities research analysts forecast that Intec Pharma will post -1.15 earnings per share for the current year.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Featured Article: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.